CGA and pancreatic neuroendocrine tumor: Of note, a recent survey in 56 ENETS centers of excellence demonstrated that a majority, i.e. 69% of the centers still use CgA and 38% PP in the screening of duodeno-pancreatic NETs in patients with MEN1 [4].